Aprea Therapeutics, Inc. [ ] Shares of Common Stock Underwriting AgreementUnderwriting Agreement • September 23rd, 2019 • Aprea Therapeutics, Inc. • Pharmaceutical preparations • New York
Aprea Therapeutics, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom you are acting as representatives (the “Representatives”), an aggregate of [ ] shares of common stock, par value $0.001 per share, of the Company (the “Underwritten Shares”). In addition, the Company proposes to issue and sell, at the option of the Underwriters, up to an additional [ ] shares of common stock of the Company (the “Option Shares”). The Underwritten Shares and the Option Shares are herein referred to as the “Shares”. The shares of common stock of the Company to be outstanding after giving effect to the sale of the Shares are referred to herein as the “Stock”.
APREA THERAPEUTICS, INC. DIRECTOR AND OFFICER INDEMNIFICATION AGREEMENTIndemnification Agreement • September 23rd, 2019 • Aprea Therapeutics, Inc. • Pharmaceutical preparations • Delaware
THIS INDEMNIFICATION AGREEMENT (this “Agreement”) is entered into as of the day of , 2019, by and between Aprea Therapeutics, Inc., a Delaware corporation (the “Company”), and (“Indemnitee”).
Customs Synthesis AgreementCustoms Synthesis Agreement • September 23rd, 2019 • Aprea Therapeutics, Inc. • Pharmaceutical preparations
SYNGENE International Private Limited (“SYNGENE”), Biocon Park, Plot Nos 2 & 3, Industrial Area, Bommasandra IV Phase, Jigani Link Road, Bangalore-560099, India,
